Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study

Entrada advances to top-dose testing in Duchenne trial; efficacy data still months away.

What the company is saying

Entrada Therapeutics is highlighting the independent Data Monitoring Committee’s recommendation to escalate dosing to 18 mg/kg in Cohort 3 of its ELEVATE-44-201 Phase 1/2 trial for ENTR-601-44, targeting Duchenne muscular dystrophy patients amenable to exon 44 skipping. The company frames this as a key clinical milestone, emphasizing the potential for higher exposure, increased dystrophin production, and functional benefit at the new dose, though these outcomes are described as possibilities rather than demonstrated results. Natarajan Sethuraman, PhD, President of Research and Development, is quoted to reinforce the narrative of steady clinical progress and deepening understanding of the drug’s profile. The announcement stresses the upcoming data readouts: Cohort 1 open-label results are expected later in 2026, and Cohort 2 data in Q1 2027. Entrada also notes prior regulatory recognition, specifically the FDA’s Rare Pediatric Disease Designation for ENTR-601-44 in December 2025. The company provides context on the target population—41,000 DMD patients in the U.S. and Europe, with about 11,500 amenable to exon 44, 45, 50, or 51 skipping—but does not present any new efficacy or safety data in this update.

What the data suggests

The disclosed facts confirm that the DMC has reviewed safety and pharmacokinetic data from eight participants in Cohort 2 and has recommended proceeding to the highest planned dose of 18 mg/kg for Cohort 3. The ELEVATE-44-201 study is a randomized, double-blind, placebo-controlled Phase 1/2 trial enrolling ambulatory participants aged 4 to 20 with DMD amenable to exon 44 skipping. The trial’s MAD Part A is being conducted at sites in the UK and EU, with three dosing cohorts: 6 mg/kg, 12 mg/kg, and now 18 mg/kg. The company reiterates that approximately 41,000 people in the U.S. and Europe have DMD, and about 11,500 are genetically eligible for exon skipping therapies like ENTR-601-44. No interim efficacy or safety outcomes are disclosed, and no financial or operational cost data are provided. The only near-term milestones are the expected release of Cohort 1 open-label data later in 2026 and Cohort 2 data in Q1 2027. All claims about functional benefit, higher exposure, or increased dystrophin production at the new dose remain forward-looking and are not yet supported by trial results.

Analysis

The announcement is positive in tone, highlighting the DMC's recommendation to escalate dosing in the ongoing Phase 1/2 study, which is a concrete operational milestone. However, the majority of the narrative focuses on future potential: anticipated higher exposure and functional benefit at the new dose, and upcoming data readouts that are not expected until late 2026 and early 2027. No efficacy or safety results are disclosed, and all clinical benefit claims remain unproven at this stage. The language around 'meaningfully higher exposure, dystrophin production, and functional benefit' is speculative, as no supporting data are provided. The update is typical for an early-stage biotech, with clear next steps but no immediate value inflection. There is no mention of large capital outlays or financial impact, so capital intensity is not flagged. Overall, the gap between narrative and evidence is moderate: the company is progressing as expected, but the most optimistic claims are forward-looking and unsubstantiated by current data.

Risk flags

• ●Clinical efficacy remains unproven, as no functional or biomarker data have been disclosed at any dose; this leaves open the possibility that higher dosing may not translate into meaningful patient benefit.
• ●Timelines for data readouts are long, with no new efficacy or safety results expected until late 2026 or early 2027, increasing the risk that interim setbacks or delays could erode momentum or investor confidence.
• ●The target population for ENTR-601-44 is a subset of the 41,000 DMD patients in the U.S. and Europe (approximately 11,500 eligible for exon skipping), which limits the potential market size and heightens the importance of demonstrating clear clinical benefit in this niche.

Bottom line

Entrada’s update signals continued progress in its Duchenne program, with the DMC’s green light to escalate to the highest planned dose in the ongoing Phase 1/2 trial. The company is transparent about trial design, dosing, and regulatory milestones, but provides no new efficacy or safety data, so the clinical value of ENTR-601-44 remains unproven. Investors should recognize that the next meaningful data will not arrive until late 2026 at the earliest, and all claims of functional benefit are still speculative. The addressable patient population is well defined but relatively small, underscoring the need for clear, positive results to justify further development. The most important takeaway is that this is a procedural milestone, not a value inflection point; the real test will come with the first efficacy data in the coming year.

Announcement summary

(NASDAQ:TRDA) Entrada Therapeutics, Inc. announced that an independent Data Monitoring Committee (DMC) has reviewed all available safety and pharmacokinetic (PK) data from the eight participants enrolled in Cohort 2 of the double-blind, placebo-controlled, multiple ascending dose (MAD) portion of the ELEVATE-44-201 clinical study. The DMC recommended initiating Cohort 3 at the top dose of 18 mg/kg, which is an increase from the 12 mg/kg dose in Cohort 2 and the 6 mg/kg dose in Cohort 1. ELEVATE-44-201 is a Phase 1/2 MAD clinical study of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy (DMD) in participants with a confirmed mutation in the DMD gene amenable to exon 44 skipping. Natarajan Sethuraman, PhD, President of Research and Development at Entrada Therapeutics, stated that the DMC's recommendation allows the company to continue dose escalation in the ELEVATE-44-201 clinical study and deepen understanding of ENTR-601-44’s safety, pharmacokinetic, and pharmacodynamic profile. Dosing at 18 mg/kg could lead to meaningfully higher exposure, dystrophin production, and functional benefit. Entrada expects to receive data later in 2026 from Cohort 1 participants after one year of treatment in the open-label period, followed by Cohort 2 data in the first quarter of 2027. ELEVATE-44-201 is a global, two-part, randomized, double-blind, placebo-controlled Phase 1/2 study evaluating the safety, tolerability, and effectiveness of ENTR-601-44 in ambulatory participants aged four to 20 with Duchenne who are amenable to exon 44 skipping. The MAD Part A portion of the study is evaluating safety, pharmacokinetics, pharmacodynamics, and functional parameters following intravenous administration of ENTR-601-44 to study participants in three cohorts at sites in the U.K. and EU. ENTR-601-44 is a proprietary Endosomal Escape Vehicle (EEV™)-conjugated oligonucleotide designed and optimized for people with a confirmed mutation in the DMD gene amenable to exon 44 skipping, which comprises approximately eight percent of the Duchenne patient population globally. ENTR-601-44 is designed to address the underlying cause of Duchenne by facilitating production of functional dystrophin from the endogenous DMD gene. In December 2025, the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease Designation to ENTR-601-44. An estimated 41,000 people in the U.S. and Europe are living with DMD. Of those, approximately 11,500 are amenable to skipping of exon 44, 45, 50, or 51. Entrada’s lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy who are exon 44, 45, 50, and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Disagree with this article?